骨保护素与心血管疾病研究进展

骨保护素（OPG）是由成骨细胞分泌的一种无跨膜结构的可溶性糖蛋白，是由Simonst等首次发现的一个肿瘤坏死因子（TNF）受体超家族的新成员。OPG是核因子-κB受体活化因子配体（RANKL）的诱导受体，OPG通过与核因子-κB 受体活化因子（RANK）的竞争性结合来阻断RANKL与RANK的结合从而抑制破骨细胞（OC）的分化成熟并诱导OC的凋亡，OPG在骨形成和骨吸收方面具有重要作用。近年来的研究表明，OPG在心血管系统中发挥着重要的调控作用，已成为心血管疾病的研究热点。现将OPG与心血管疾病的相关研究进展做相关阐述。

Research progress of osteoprotegerin in cardiovascular disease

Osteoprotegerin （OPG）, a new member of tumor necrosis factor （TNF） receptor superfamily, is a soluble non-transmembrane glycoprotein secreted by osteoblasts, which was first discovered by Simonst. OPG is the receptor activator of nuclear factor-κB factor ligand （RANKL） induced receptor, competitively inhibits the combination of RANKL and receptor activator of NF-κB （RANK）. It can inhibit osteoclast＇s （OC） differentiation, maturation and induce osteoclast apoptosis. OPG plays an important role in the formation and resorption of bone. Recent studies show that OPG plays important roles in the regulation of the cardiovascular system, and it has become a hot research topic in cardiovascular disease. In this review, we will do the related elaboration of research progress of OPG and cardiovascular diseases.